Freetown
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 9 / 7.6 / 117.9 / (53.8-223.9) / Male / 3 / 4.7 / nc / (nc-nc)
Female / 1 / 2.5 / nc / (nc-nc) / Female / 5 / 3.8 / 133.1 / (42.9-310.7)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 1.7 / nc / (nc-nc) / Male / 0 / 1.2 / nc / (nc-nc)
Female / 1 / 1.4 / nc / (nc-nc) / Female / 2 / 0.8 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 5 / 4.4 / 114.4 / (36.9-267.0)
Female / 28 / 31.9 / 87.8 / (58.3-126.8) / Female / 2 / 3.5 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 3 / 3.5 / nc / (nc-nc)
Female / 2 / 1.5 / nc / (nc-nc) / Female / 2 / 1.5 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 13 / 12.0 / 108.1 / (57.5-184.8)
Female / 6 / 9.9 / 60.5 / (22.1-131.7) / Female / 3 / 3.3 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 2.1 / nc / (nc-nc) / Male / 2 / 2.3 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 0 / 2.1 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.8 / nc / (nc-nc) / Male / 36 / 33.7 / 106.8 / (74.8-147.8)
Female / 0 / 0.6 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 2 / 3.6 / nc / (nc-nc) / Male / 1 / 2.0 / nc / (nc-nc)
Female / 1 / 2.0 / nc / (nc-nc) / Female / 1 / 1.0 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 1.5 / nc / (nc-nc) / Male / 2 / 1.4 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc)
Leukemia / Thyroid
Male / 3 / 2.6 / nc / (nc-nc) / Male / 0 / 1.0 / nc / (nc-nc)
Female / 3 / 1.9 / nc / (nc-nc) / Female / 4 / 3.3 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 1.7 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 4 / 6.4 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 18 / 15.1 / 119.4 / (70.7-188.7) / Male / 111 / 110.4 / 100.5 / (82.7-121.0)
Female / 9 / 12.5 / 72.2 / (33.0-137.1) / Female / 77 / 97.7 / 78.8 / (62.2-98.5)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
111
Gardner
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 27 / 24.9 / 108.6 / (71.6-158.0) / Male / 5 / 13.0 / 38.4 / (12.4-89.6)
Female / 7 / 9.0 / 78.1 / (31.3-161.0) / Female / 2 / 9.8 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 4.6 / nc / (nc-nc) / Male / 0 / 3.6 / nc / (nc-nc)
Female / 2 / 3.8 / nc / (nc-nc) / Female / 3 / 2.9 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 3 / 0.8 / nc / (nc-nc) / Male / 10 / 12.6 / 79.4 / (38.0-146.1)
Female / 85 / 84.0 / 101.2 / (80.9-125.2) / Female / 7 / 11.3 / 61.9 / (24.8-127.6)
Cervix Uteri / Oral Cavity & Pharynx
Male / 8 / 8.8 / 90.6 / (39.0-178.5)
Female / 2 / 3.6 / nc / (nc-nc) / Female / 6 / 4.4 / 137.2 / (50.1-298.7)
Colon / Rectum / Ovary
Male / 31 / 37.3 / 83.1 / (56.4-117.9)
Female / 30 / 37.4 / 80.2 / (54.1-114.5) / Female / 14 / 9.1 / 154.3 / (84.3-258.8)
Esophagus / Pancreas
Male / 4 / 6.0 / nc / (nc-nc) / Male / 7 / 7.0 / 99.9 / (40.0-205.7)
Female / 2 / 1.8 / nc / (nc-nc) / Female / 10 / 7.9 / 126.1 / (60.3-231.8)
Hodgkin Lymphoma / Prostate
Male / 1 / 2.0 / nc / (nc-nc) / Male / 86 / 94.8 / 90.8 / (72.6-112.1)
Female / 0 / 1.5 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 10 / 9.8 / 101.8 / (48.7-187.2) / Male / 2 / 6.3 / nc / (nc-nc)
Female / 3 / 6.2 / nc / (nc-nc) / Female / 2 / 4.0 / nc / (nc-nc)
Larynx / Testis
Male / 6 / 4.1 / 146.2 / (53.4-318.3) / Male / 1 / 3.7 / nc / (nc-nc)
Female / 0 / 1.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 8 / 7.7 / 103.8 / (44.7-204.6) / Male / 2 / 2.6 / nc / (nc-nc)
Female / 4 / 6.4 / nc / (nc-nc) / Female / 8 / 7.3 / 108.8 / (46.9-214.5)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 4.6 / nc / (nc-nc)
Female / 1 / 1.8 / nc / (nc-nc) / Female / 18 / 16.8 / 107.1 / (63.4-169.2)
Lung and Bronchus / All Sites / Types
Male / 49 / 46.3 / 105.9 / (78.3-140.0) / Male / 290 / 322.6 / 89.9 / (79.9-100.9)
Female / 40 / 41.2 / 97.1 / (69.4-132.2) / Female / 267 / 294.3 / 90.7 / (80.2-102.3)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
112
Georgetown
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 5 / 6.3 / 79.9 / (25.8-186.6) / Male / 5 / 3.9 / 128.7 / (41.5-300.3)
Female / 1 / 2.1 / nc / (nc-nc) / Female / 6 / 3.2 / 188.9 / (69.0-411.2)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 1.5 / nc / (nc-nc) / Male / 2 / 1.0 / nc / (nc-nc)
Female / 1 / 1.2 / nc / (nc-nc) / Female / 0 / 0.7 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 8 / 3.6 / 222.9 / (96.0-439.2)
Female / 28 / 26.7 / 105.0 / (69.8-151.8) / Female / 5 / 3.0 / 167.7 / (54.0-391.3)
Cervix Uteri / Oral Cavity & Pharynx
Male / 2 / 2.9 / nc / (nc-nc)
Female / 1 / 1.3 / nc / (nc-nc) / Female / 2 / 1.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 12 / 9.8 / 121.9 / (62.9-212.9)
Female / 12 / 8.7 / 138.3 / (71.4-241.6) / Female / 3 / 2.7 / nc / (nc-nc)
Esophagus / Pancreas
Male / 4 / 1.7 / nc / (nc-nc) / Male / 4 / 1.9 / nc / (nc-nc)
Female / 1 / 0.4 / nc / (nc-nc) / Female / 2 / 1.8 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 0.6 / nc / (nc-nc) / Male / 24 / 27.2 / 88.2 / (56.5-131.3)
Female / 0 / 0.5 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 1 / 3.0 / nc / (nc-nc) / Male / 1 / 1.6 / nc / (nc-nc)
Female / 0 / 1.7 / nc / (nc-nc) / Female / 0 / 0.9 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 1.2 / nc / (nc-nc) / Male / 4 / 1.1 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 2.2 / nc / (nc-nc) / Male / 1 / 0.9 / nc / (nc-nc)
Female / 1 / 1.7 / nc / (nc-nc) / Female / 3 / 2.9 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 1.4 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 4 / 5.3 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 19 / 12.3 / 154.3 / (92.8-241.0) / Male / 104 / 90.1 / 115.4 / (94.3-139.9)
Female / 10 / 10.6 / 94.7 / (45.3-174.2) / Female / 84 / 83.0 / 101.2 / (80.7-125.3)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
113
Gill
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 2 / 1.5 / nc / (nc-nc) / Male / 1 / 0.9 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 0 / 0.7 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 1 / 0.2 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 2 / 0.8 / nc / (nc-nc)
Female / 5 / 6.0 / 83.7 / (27.0-195.4) / Female / 2 / 0.7 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 0.6 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 2 / 2.4 / nc / (nc-nc)
Female / 2 / 2.1 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.4 / nc / (nc-nc) / Male / 1 / 0.4 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 1 / 0.4 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 5 / 6.1 / 82.3 / (26.5-192.0)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 1 / 0.7 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 1 / 0.2 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.5 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 2 / 1.2 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 1 / 2.9 / nc / (nc-nc) / Male / 17 / 20.7 / 82.2 / (47.8-131.6)
Female / 4 / 2.5 / nc / (nc-nc) / Female / 18 / 19.0 / 94.9 / (56.2-150.0)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
114
Gloucester
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 36 / 35.4 / 101.8 / (71.3-140.9) / Male / 15 / 19.0 / 79.1 / (44.2-130.4)
Female / 15 / 13.4 / 112.1 / (62.7-184.9) / Female / 14 / 15.7 / 89.3 / (48.8-149.8)
Brain and Other Nervous System / Multiple Myeloma
Male / 5 / 6.6 / 76.2 / (24.6-177.9) / Male / 4 / 5.2 / nc / (nc-nc)
Female / 8 / 5.9 / 135.0 / (58.1-266.0) / Female / 7 / 4.4 / 160.0 / (64.1-329.6)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 1.1 / nc / (nc-nc) / Male / 21 / 18.1 / 116.2 / (71.9-177.6)
Female / 128 / 137.1 / 93.4 / (77.9-111.0) / Female / 15 / 17.2 / 87.1 / (48.7-143.7)
Cervix Uteri / Oral Cavity & Pharynx
Male / 22 / 13.6 / 162.1 / (101.5-245.4)
Female / 6 / 5.9 / 102.0 / (37.2-222.0) / Female / 5 / 6.9 / 72.6 / (23.4-169.5)
Colon / Rectum / Ovary
Male / 48 / 53.7 / 89.4 / (65.9-118.5)
Female / 70 / 55.0 / 127.3 / (99.2-160.9) / Female / 11 / 14.5 / 75.8 / (37.8-135.6)
Esophagus / Pancreas
Male / 9 / 8.9 / 101.4 / (46.3-192.4) / Male / 19 / 10.2 / 187.0 / (112.5-292.1)
Female / 1 / 2.6 / nc / (nc-nc) / Female / 12 / 11.6 / 103.1 / (53.2-180.1)
Hodgkin Lymphoma / Prostate
Male / 3 / 2.7 / nc / (nc-nc) / Male / 139 / 145.1 / 95.8 / (80.6-113.1)
Female / 5 / 2.3 / 216.6 / (69.8-505.4)
Kidney & Renal Pelvis / Stomach
Male / 14 / 14.7 / 95.1 / (51.9-159.5) / Male / 8 / 9.0 / 88.8 / (38.2-174.9)
Female / 12 / 9.7 / 123.3 / (63.6-215.4) / Female / 7 / 5.8 / 120.7 / (48.3-248.6)
Larynx / Testis
Male / 9 / 6.2 / 144.6 / (66.0-274.4) / Male / 7 / 4.6 / 150.7 / (60.4-310.6)
Female / 2 / 1.8 / nc / (nc-nc)
Leukemia / Thyroid
Male / 16 / 10.9 / 146.7 / (83.8-238.2) / Male / 5 / 3.8 / 132.9 / (42.8-310.1)
Female / 8 / 9.5 / 83.9 / (36.1-165.3) / Female / 15 / 12.2 / 123.1 / (68.8-203.0)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 9 / 6.9 / 130.3 / (59.5-247.4)
Female / 2 / 2.7 / nc / (nc-nc) / Female / 24 / 27.9 / 86.0 / (55.1-128.0)
Lung and Bronchus / All Sites / Types
Male / 72 / 67.8 / 106.3 / (83.1-133.8) / Male / 508 / 474.6 / 107.0 / (97.9-116.8)
Female / 69 / 63.6 / 108.4 / (84.3-137.2) / Female / 468 / 460.1 / 101.7 / (92.7-111.4)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
115
Goshen
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 0 / 1.0 / nc / (nc-nc) / Male / 0 / 0.6 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.5 / nc / (nc-nc)
Female / 1 / 3.9 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 0.4 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 0 / 1.6 / nc / (nc-nc)
Female / 0 / 1.3 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 0.3 / nc / (nc-nc) / Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 6 / 4.4 / 135.7 / (49.5-295.3)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 2 / 0.5 / nc / (nc-nc) / Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.3 / nc / (nc-nc) / Male / 1 / 0.1 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 1 / 0.4 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 1 / 0.8 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 0 / 2.0 / nc / (nc-nc) / Male / 12 / 14.3 / 84.0 / (43.3-146.7)
Female / 2 / 1.5 / nc / (nc-nc) / Female / 6 / 12.1 / 49.6 / (18.1-107.9)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
116
Gosnold
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 1 / 0.1 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.0 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.0 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 0 / 0.0 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.0 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.0 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.0 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.7 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 1 / 0.1 / nc / (nc-nc) / Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.0 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.0 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 0 / 0.3 / nc / (nc-nc) / Male / 2 / 2.0 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 1.1 / nc / (nc-nc)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
117
Grafton
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 11 / 13.7 / 80.1 / (40.0-143.4) / Male / 7 / 7.9 / 89.1 / (35.7-183.6)
Female / 7 / 4.9 / 142.5 / (57.1-293.6) / Female / 4 / 6.7 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 2.9 / nc / (nc-nc) / Male / 3 / 2.0 / nc / (nc-nc)
Female / 0 / 2.5 / nc / (nc-nc) / Female / 2 / 1.6 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.4 / nc / (nc-nc) / Male / 7 / 7.4 / 94.0 / (37.6-193.6)
Female / 75 / 55.3 / 135.5 / (106.6-169.9) / Female / 7 / 6.7 / 104.6 / (41.9-215.6)
Cervix Uteri / Oral Cavity & Pharynx
Male / 3 / 5.5 / nc / (nc-nc)
Female / 1 / 2.6 / nc / (nc-nc) / Female / 3 / 2.7 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 18 / 21.1 / 85.5 / (50.6-135.1)
Female / 20 / 20.1 / 99.6 / (60.8-153.8) / Female / 5 / 5.8 / 86.3 / (27.8-201.4)
Esophagus / Pancreas
Male / 2 / 3.5 / nc / (nc-nc) / Male / 6 / 4.0 / 150.8 / (55.1-328.3)
Female / 2 / 1.0 / nc / (nc-nc) / Female / 3 / 4.2 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 1.3 / nc / (nc-nc) / Male / 41 / 56.0 / 73.2 / (52.5-99.3)
Female / 0 / 1.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 6 / 5.9 / 100.9 / (36.8-219.5) / Male / 3 / 3.5 / nc / (nc-nc)
Female / 5 / 3.8 / 131.5 / (42.4-306.8) / Female / 3 / 2.1 / nc / (nc-nc)
Larynx / Testis
Male / 1 / 2.5 / nc / (nc-nc) / Male / 1 / 2.4 / nc / (nc-nc)
Female / 0 / 0.7 / nc / (nc-nc)
Leukemia / Thyroid
Male / 4 / 4.5 / nc / (nc-nc) / Male / 2 / 1.7 / nc / (nc-nc)
Female / 2 / 3.8 / nc / (nc-nc) / Female / 5 / 5.8 / 86.6 / (27.9-202.0)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 2.8 / nc / (nc-nc)
Female / 0 / 1.0 / nc / (nc-nc) / Female / 14 / 11.1 / 125.9 / (68.8-211.2)
Lung and Bronchus / All Sites / Types
Male / 25 / 26.4 / 94.6 / (61.2-139.7) / Male / 151 / 188.1 / 80.3 / (68.0-94.1)
Female / 23 / 24.1 / 95.4 / (60.5-143.2) / Female / 187 / 180.6 / 103.6 / (89.2-119.5)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
118
Granby
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 6 / 6.1 / 97.6 / (35.6-212.4) / Male / 2 / 3.5 / nc / (nc-nc)
Female / 0 / 2.0 / nc / (nc-nc) / Female / 2 / 2.8 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 1 / 1.3 / nc / (nc-nc) / Male / 0 / 0.9 / nc / (nc-nc)
Female / 1 / 1.0 / nc / (nc-nc) / Female / 1 / 0.7 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 2 / 0.2 / nc / (nc-nc) / Male / 2 / 3.3 / nc / (nc-nc)
Female / 23 / 23.5 / 97.8 / (62.0-146.7) / Female / 0 / 2.7 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 5 / 2.5 / 196.4 / (63.3-458.3)
Female / 1 / 1.1 / nc / (nc-nc) / Female / 0 / 1.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 8 / 9.5 / 84.5 / (36.4-166.5)
Female / 8 / 8.0 / 99.8 / (43.0-196.7) / Female / 0 / 2.4 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 1.6 / nc / (nc-nc) / Male / 2 / 1.8 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 1 / 1.7 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.5 / nc / (nc-nc) / Male / 21 / 26.2 / 80.1 / (49.5-122.4)
Female / 0 / 0.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 4 / 2.7 / nc / (nc-nc) / Male / 1 / 1.6 / nc / (nc-nc)
Female / 0 / 1.6 / nc / (nc-nc) / Female / 0 / 0.8 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 1.1 / nc / (nc-nc) / Male / 1 / 1.0 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc)
Leukemia / Thyroid
Male / 2 / 2.0 / nc / (nc-nc) / Male / 2 / 0.7 / nc / (nc-nc)
Female / 1 / 1.5 / nc / (nc-nc) / Female / 2 / 2.4 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 1.3 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 5 / 4.8 / 104.9 / (33.8-244.8)
Lung and Bronchus / All Sites / Types
Male / 14 / 12.0 / 116.3 / (63.5-195.1) / Male / 78 / 85.5 / 91.2 / (72.1-113.8)
Female / 11 / 10.0 / 110.0 / (54.8-196.8) / Female / 59 / 74.9 / 78.8 / (60.0-101.7)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
119
Granville
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 1 / 1.4 / nc / (nc-nc) / Male / 0 / 0.9 / nc / (nc-nc)
Female / 1 / 0.5 / nc / (nc-nc) / Female / 1 / 0.7 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 1 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 1 / 0.8 / nc / (nc-nc)
Female / 6 / 5.7 / 104.7 / (38.2-228.0) / Female / 1 / 0.6 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.6 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 1 / 2.2 / nc / (nc-nc)
Female / 2 / 1.9 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.4 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 4 / 6.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.7 / nc / (nc-nc) / Male / 1 / 0.4 / nc / (nc-nc)
Female / 1 / 0.4 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.3 / nc / (nc-nc) / Male / 2 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.5 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 1 / 0.3 / nc / (nc-nc) / Female / 1 / 0.6 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 1.2 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 3 / 2.9 / nc / (nc-nc) / Male / 16 / 20.6 / 77.8 / (44.4-126.3)
Female / 2 / 2.4 / nc / (nc-nc) / Female / 18 / 17.9 / 100.7 / (59.7-159.2)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
120
Great Barrington
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 8 / 9.9 / 80.7 / (34.7-159.0) / Male / 7 / 5.0 / 141.1 / (56.5-290.7)
Female / 3 / 4.0 / nc / (nc-nc) / Female / 4 / 4.2 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 1 / 1.7 / nc / (nc-nc) / Male / 0 / 1.4 / nc / (nc-nc)
Female / 1 / 1.6 / nc / (nc-nc) / Female / 1 / 1.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.3 / nc / (nc-nc) / Male / 6 / 4.8 / 124.0 / (45.3-269.9)
Female / 26 / 37.9 / 68.6 / (44.8-100.5) / Female / 2 / 5.1 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 4 / 3.5 / nc / (nc-nc)
Female / 0 / 1.5 / nc / (nc-nc) / Female / 2 / 2.0 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 13 / 14.9 / 87.3 / (46.4-149.3)
Female / 16 / 17.2 / 93.2 / (53.2-151.3) / Female / 4 / 4.1 / nc / (nc-nc)
Esophagus / Pancreas
Male / 2 / 2.4 / nc / (nc-nc) / Male / 3 / 2.8 / nc / (nc-nc)
Female / 1 / 0.8 / nc / (nc-nc) / Female / 3 / 3.6 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.7 / nc / (nc-nc) / Male / 46 / 37.6 / 122.4 / (89.6-163.3)
Female / 0 / 0.6 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 3 / 3.8 / nc / (nc-nc) / Male / 1 / 2.5 / nc / (nc-nc)
Female / 4 / 2.8 / nc / (nc-nc) / Female / 1 / 1.9 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 1.6 / nc / (nc-nc) / Male / 1 / 1.0 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 2.9 / nc / (nc-nc) / Male / 0 / 0.9 / nc / (nc-nc)
Female / 2 / 2.8 / nc / (nc-nc) / Female / 1 / 3.0 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 1.8 / nc / (nc-nc)
Female / 0 / 0.8 / nc / (nc-nc) / Female / 7 / 7.7 / 91.3 / (36.6-188.0)
Lung and Bronchus / All Sites / Types
Male / 19 / 18.3 / 104.1 / (62.6-162.5) / Male / 127 / 126.6 / 100.3 / (83.6-119.3)
Female / 17 / 18.4 / 92.4 / (53.8-147.9) / Female / 110 / 132.3 / 83.2 / (68.3-100.2)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
121
Greenfield
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 19 / 22.0 / 86.4 / (52.0-135.0) / Male / 6 / 11.2 / 53.6 / (19.6-116.7)
Female / 15 / 9.2 / 163.2 / (91.3-269.2) / Female / 7 / 9.7 / 72.2 / (28.9-148.7)
Brain and Other Nervous System / Multiple Myeloma
Male / 3 / 3.8 / nc / (nc-nc) / Male / 4 / 3.1 / nc / (nc-nc)
Female / 3 / 3.8 / nc / (nc-nc) / Female / 2 / 3.0 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.7 / nc / (nc-nc) / Male / 9 / 10.9 / 82.5 / (37.6-156.6)
Female / 88 / 84.8 / 103.8 / (83.2-127.9) / Female / 13 / 11.5 / 112.7 / (60.0-192.8)
Cervix Uteri / Oral Cavity & Pharynx
Male / 3 / 7.7 / nc / (nc-nc)
Female / 9 / 3.5 / 257.1 / (117.3-488.1) / Female / 2 / 4.4 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 25 / 33.0 / 75.8 / (49.1-112.0)
Female / 40 / 39.4 / 101.5 / (72.5-138.3) / Female / 9 / 9.2 / 97.7 / (44.6-185.5)
Esophagus / Pancreas
Male / 2 / 5.2 / nc / (nc-nc) / Male / 6 / 6.2 / 96.9 / (35.4-211.0)
Female / 1 / 1.8 / nc / (nc-nc) / Female / 8 / 8.3 / 96.7 / (41.6-190.6)
Hodgkin Lymphoma / Prostate
Male / 0 / 1.6 / nc / (nc-nc) / Male / 67 / 81.3 / 82.4 / (63.9-104.7)
Female / 3 / 1.5 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 6 / 8.5 / 70.6 / (25.8-153.6) / Male / 6 / 5.6 / 107.3 / (39.2-233.5)
Female / 4 / 6.3 / nc / (nc-nc) / Female / 0 / 4.3 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 3.6 / nc / (nc-nc) / Male / 4 / 2.7 / nc / (nc-nc)
Female / 0 / 1.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 3 / 6.7 / nc / (nc-nc) / Male / 0 / 2.1 / nc / (nc-nc)
Female / 5 / 6.5 / 76.4 / (24.6-178.2) / Female / 4 / 7.1 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 5 / 4.0 / 125.5 / (40.4-292.9)
Female / 1 / 1.9 / nc / (nc-nc) / Female / 15 / 16.7 / 89.6 / (50.1-147.8)
Lung and Bronchus / All Sites / Types
Male / 38 / 40.5 / 93.9 / (66.5-128.9) / Male / 223 / 279.9 / 79.7 / (69.6-90.8)
Female / 49 / 41.2 / 119.0 / (88.0-157.3) / Female / 305 / 299.3 / 101.9 / (90.8-114.0)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
122
Groton
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 12 / 6.8 / 176.5 / (91.1-308.3) / Male / 4 / 4.5 / nc / (nc-nc)
Female / 0 / 2.2 / nc / (nc-nc) / Female / 3 / 3.7 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 1.7 / nc / (nc-nc) / Male / 0 / 1.1 / nc / (nc-nc)
Female / 0 / 1.4 / nc / (nc-nc) / Female / 0 / 0.7 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 7 / 4.1 / 170.6 / (68.3-351.5)
Female / 43 / 30.6 / 140.6 / (101.8-189.5) / Female / 3 / 3.3 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 4 / 3.2 / nc / (nc-nc)
Female / 1 / 1.6 / nc / (nc-nc) / Female / 1 / 1.4 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 12 / 10.8 / 111.1 / (57.4-194.2)
Female / 11 / 9.1 / 120.8 / (60.2-216.2) / Female / 1 / 3.1 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 1.9 / nc / (nc-nc) / Male / 0 / 2.1 / nc / (nc-nc)
Female / 1 / 0.4 / nc / (nc-nc) / Female / 1 / 1.9 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.8 / nc / (nc-nc) / Male / 37 / 29.1 / 127.2 / (89.5-175.3)
Female / 0 / 0.6 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 5 / 3.3 / 150.2 / (48.4-350.4) / Male / 1 / 1.8 / nc / (nc-nc)
Female / 3 / 1.9 / nc / (nc-nc) / Female / 0 / 0.9 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 1.3 / nc / (nc-nc) / Male / 1 / 1.5 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc)
Leukemia / Thyroid
Male / 2 / 2.5 / nc / (nc-nc) / Male / 0 / 1.0 / nc / (nc-nc)
Female / 0 / 1.9 / nc / (nc-nc) / Female / 3 / 3.5 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 1.6 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 5 / 5.9 / 84.6 / (27.3-197.5)
Lung and Bronchus / All Sites / Types
Male / 10 / 13.4 / 74.8 / (35.8-137.6) / Male / 105 / 99.3 / 105.8 / (86.5-128.1)
Female / 4 / 11.2 / nc / (nc-nc) / Female / 86 / 92.5 / 93.0 / (74.4-114.8)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
123
Groveland
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 10 / 5.5 / 183.0 / (87.6-336.6) / Male / 4 / 3.2 / nc / (nc-nc)
Female / 1 / 1.8 / nc / (nc-nc) / Female / 1 / 2.6 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 1.2 / nc / (nc-nc) / Male / 0 / 0.8 / nc / (nc-nc)
Female / 0 / 1.0 / nc / (nc-nc) / Female / 1 / 0.6 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 3 / 3.0 / nc / (nc-nc)
Female / 28 / 22.0 / 127.1 / (84.4-183.6) / Female / 2 / 2.5 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 2.3 / nc / (nc-nc)
Female / 1 / 1.1 / nc / (nc-nc) / Female / 0 / 1.0 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 11 / 8.5 / 130.1 / (64.9-232.8)
Female / 11 / 7.3 / 151.2 / (75.4-270.5) / Female / 4 / 2.3 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 1.4 / nc / (nc-nc) / Male / 1 / 1.6 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 0 / 1.5 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.5 / nc / (nc-nc) / Male / 27 / 23.5 / 115.1 / (75.8-167.4)
Female / 0 / 0.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 2 / 2.5 / nc / (nc-nc) / Male / 2 / 1.4 / nc / (nc-nc)
Female / 1 / 1.5 / nc / (nc-nc) / Female / 0 / 0.8 / nc / (nc-nc)
Larynx / Testis
Male / 1 / 1.0 / nc / (nc-nc) / Male / 1 / 0.9 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 1.8 / nc / (nc-nc) / Male / 1 / 0.7 / nc / (nc-nc)
Female / 1 / 1.4 / nc / (nc-nc) / Female / 1 / 2.3 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 1.2 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 6 / 4.4 / 136.9 / (50.0-297.9)
Lung and Bronchus / All Sites / Types
Male / 12 / 10.8 / 111.4 / (57.5-194.5) / Male / 86 / 77.1 / 111.6 / (89.2-137.8)
Female / 15 / 9.0 / 167.2 / (93.5-275.8) / Female / 77 / 69.1 / 111.5 / (88.0-139.3)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
124
Hadley
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003
Bladder, Urinary / Melanoma of Skin
Male / 4 / 6.9 / nc / (nc-nc) / Male / 4 / 3.4 / nc / (nc-nc)
Female / 2 / 2.5 / nc / (nc-nc) / Female / 3 / 2.7 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 1.1 / nc / (nc-nc) / Male / 3 / 1.0 / nc / (nc-nc)
Female / 2 / 1.0 / nc / (nc-nc) / Female / 0 / 0.8 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.2 / nc / (nc-nc) / Male / 3 / 3.3 / nc / (nc-nc)
Female / 26 / 23.9 / 108.8 / (71.1-159.5) / Female / 7 / 3.2 / 220.4 / (88.3-454.2)
Cervix Uteri / Oral Cavity & Pharynx
Male / 4 / 2.3 / nc / (nc-nc)
Female / 0 / 1.0 / nc / (nc-nc) / Female / 0 / 1.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 9 / 10.3 / 87.4 / (39.9-166.0)
Female / 11 / 10.7 / 102.7 / (51.2-183.8) / Female / 2 / 2.6 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 1.6 / nc / (nc-nc) / Male / 4 / 1.9 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 2 / 2.3 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 2 / 0.4 / nc / (nc-nc) / Male / 27 / 25.1 / 107.7 / (70.9-156.7)
Female / 0 / 0.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 2 / 2.6 / nc / (nc-nc) / Male / 2 / 1.7 / nc / (nc-nc)
Female / 2 / 1.7 / nc / (nc-nc) / Female / 3 / 1.2 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 1.1 / nc / (nc-nc) / Male / 0 / 0.7 / nc / (nc-nc)
Female / 1 / 0.3 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 2.0 / nc / (nc-nc) / Male / 1 / 0.6 / nc / (nc-nc)
Female / 1 / 1.8 / nc / (nc-nc) / Female / 3 / 2.0 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 1.2 / nc / (nc-nc)
Female / 1 / 0.5 / nc / (nc-nc) / Female / 2 / 4.8 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 8 / 12.6 / 63.3 / (27.3-124.7) / Male / 84 / 86.2 / 97.4 / (77.7-120.6)
Female / 8 / 11.5 / 69.3 / (29.9-136.6) / Female / 81 / 83.0 / 97.6 / (77.5-121.3)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
125